Roivant Sciences (ROIV)
Health Care · Biotechnology · NASDAQ
Roivant Sciences is a biopharma company that accelerates drug development through a decentralized model of nimble, independent 'Vant' subsidiaries and proprietary computational tools.
What Roivant Sciences does
Roivant Sciences is a biopharmaceutical company that utilizes a decentralized 'Vant' subsidiary model to accelerate the development and commercialization of innovative medicines. The company maintains a diversified pipeline targeting autoimmune and inflammatory diseases, with lead candidates including a JAK1/TYK2 inhibitor and an anti-FcRn monoclonal antibody. Beyond clinical therapeutics, Roivant also incubates discovery-stage ventures and health technology startups.
Themes: Autoimmune diseases, Inflammatory diseases, Drug development platform, Biotechnology incubation, Health technology, JAK1/TYK2 inhibitors, FcRn targeted therapies
Fundamentals
- Price$34.21 as of 2026-10-08 close
- Market cap$24.7B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+113.4% 2025-10-08 close $16.03 → 2026-10-08 close $34.21
- P/En/a negative earnings
- Net margin-3629.2% FY2026, SEC XBRL
- ROE-5.7% FY2026, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-67.6% as of 2026-09-02
- Revenue CAGR (3y)-36.0% SEC XBRL
- Beta0.87 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ROIV compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ROIV is not currently in any published Top 10 list. Its scores are below.
Top 10 score
32.7 #1321 of 1,379 scored · #143 of 151 in Health Care
Trend 73rd (over the past 12 months this stock beat the market by 98.4 percentage points) and capital return 52nd (net share count bought back over the year 4.4, consecutive years of dividend increases 0 years); weakest is growth (1st, 3-year revenue CAGR -36%, revenue growth year over year -67.6%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Roivant Sciences looks technically
Roivant Sciences (ROIV) is trading 13.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 301 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-09-02, breaking below its recent trading range. It is 19.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 13.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $36.66 | $36.66 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $30.28 | $30.28 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 42.5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 301 trading days ago — a "golden cross", a bullish long-term signal | 301 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 16.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($33.32 to $39.90) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $42.50 | $42.50 |
|---|---|---|
| From the 52-week high | it is 19.5% below its 52-week high (its highest price of the past year) | -19.5% |
| Above the 52-week low | it is 126.4% above its 52-week low (its lowest price of the past year) | +126.4% |
| Below the 52-week high | it is 19.5% below its highest point of the past year | 19.5% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-09-02, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 22 trading days ago | 22 sessions |
| All-time high | its highest closing price on record is $42.50 (set on 2026-09-08) | $42.50 |
| Given back of the 52-week move | over the past year its closes ranged ($15.75 to $41.81), and it has given back roughly a quarter of its rise from last year’s low — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.87 to $25.70. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 29.2% |
| From the all-time high | it is 19.5% below its all-time high | -19.5% |
| Nearest price level | it is trading 2.1% above a support level at $33.49 — a price it turned at twice since 2026-07-17, most recently on 2026-09-02. Since 2024-10-08 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.1% |
| All-time low | its lowest closing price on record is $2.52 (set on 2022-05-12) | $2.52 |
| Above the all-time low | it is 1257.5% above its all-time low | +1,258% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.33 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.33 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $33.28 and $41.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $33.28 – $37.41 – $41.54 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges above its 200-day average price (13.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.8% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -4.39% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.6 percentage points (the stock lost 17.5% while the market gained 1.0%) | -18.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.0 percentage points (the stock lost 5.2% while the market gained 3.8%) | -9.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 5.3 percentage points (the stock gained 22.7% while the market gained 17.5%) | +5.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 98.4 percentage points (the stock gained 113.4% while the market gained 15.0%) | +98.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.8% of the share price. | -0.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $31.34 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +9.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $37.26 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -8.2% |
Price levels it has turned at before
ROIV last closed at $34.21 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $33.49 | Support | 2.1% below the last close | turned there twice · 2026-07-17 to 2026-09-02 |
| $32.63 | Support | 4.6% below the last close | turned there twice · 2026-05-20 to 2026-08-03 |
| $37.89 | Resistance | 10.8% above the last close | turned there twice · 2026-08-19 to 2026-08-27 |
| $30.10 | Support | 12.0% below the last close | turned there three times · 2026-03-11 to 2026-05-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $42.50.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 12 trading days, since 2026-09-23.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Printed a doji candle · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.31 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$48.08 range $41.00 – $55.00; median $46.50
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ROIV
- Consensus EPS estimate-$0.4505 next reporting period, as of 2026-10-05
- Estimate change, 30 days$0.00 from -$0.4505, on 2026-08-31, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on the successful clinical and regulatory outcomes of key product candidates like brepocitinib and IMVT-1402.","Inherent financial risk and potential need for additional capital due to an expensive, long-term drug development lifecycle and significant operating losses.","Risks related to the 'Vant' structure, including the ability to effectively allocate capital and personnel across multiple independent subsidiaries."]
What changed in the latest 10-Q
AI-assisted comparison of ROIV's 10-Q filed 2026-02-06 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Pipeline table: Brepocitinib Dermatomyositis phase changed to 'NDA Filed' (newer filing, 2026-02-06)
- Pipeline table: Brepocitinib Cutaneous Sarcoidosis phase changed to 'Phase 3*' (newer filing, 2026-02-06)
- Vant Ownership table: Updated to December 31, 2025 date (newer filing, 2026-02-06); older filing showed September 30, 2025
- Vant Ownership: Priovant fully diluted ownership increased from 65% to 66% (newer filing, 2026-02-06)
- Vant Ownership: Immunovant basic ownership increased from 55% to 56% (newer filing, 2026-02-06)
- Vant Ownership: Immunovant fully diluted ownership increased from 50% to 52% (newer filing, 2026-02-06)
- Vant Ownership: Covant fully diluted ownership increased from 90% to 91% (newer filing, 2026-02-06)
- Vant Ownership note: Reference to 'Proxima (formerly VantAI)' and 'PsiThera (formerly Psivant)' added (newer filing, 2026-02-06)
- Upcoming Catalysts table: Jury trial timing changed from '1Q 2026' to 'March 2026' (newer filing, 2026-02-06)
- Upcoming Catalysts table: 'Topline data released from Phase 3 trials' language changed to 'Topline data from both Phase 3 trials' (newer filing, 2026-02-06)
- Upcoming Catalysts table: Brepocitinib NDA filing catalyst removed from 1H 2026 timing (newer filing, 2026-02-06)
- Upcoming Catalysts table: Brepocitinib Phase 2 trial in cutaneous sarcoidosis catalyst removed (newer filing, 2026-02-06)
- Upcoming Catalysts table: IMVT-1402 'Initial results from open label period' catalyst removed (newer filing, 2026-02-06)
- Upcoming Catalysts table: IMVT-1402 cutaneous lupus timing changed from '2026' to '2H 2026' (newer filing, 2026-02-06)
- Upcoming Catalysts table: IMVT-1402 difficult-to-treat rheumatoid arthritis catalyst language changed and timing moved to '2H 2026' (newer filing, 2026-02-06)
- Upcoming Catalysts table: Brepocitinib non-infectious uveitis timing changed from '1H 2027' to '2H 2026' (newer filing, 2026-02-06)
- Upcoming Catalysts table: IMVT-1402 potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis removed from 2027 (newer filing, 2026-02-06)
- Upcoming Catalysts table: IMVT-1402 chronic inflammatory demyelinating polyneuropathy timing changed from 2028 to 2028 with adjusted description (newer filing, 2026-02-06)
- Recent Developments - Priovant: Added positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (newer filing, 2026-02-06)
- Recent Developments - Priovant: NDA submission for brepocitinib in dermatomyositis stated as completed (newer filing, 2026-02-06)
- Recent Developments - Priovant: Brepocitinib non-infectious uveitis timing changed from '1H 2027' to 'second half of calendar year 2026' (newer filing, 2026-02-06)
- Recent Developments - Immunovant: Added language about Roivant-led financing generating approximately $550 million (newer filing, 2026-02-06)
- Recent Developments - Pulmovant: Added language stating Phase 2 trial 'fully enrolled' (newer filing, 2026-02-06)
- Recent Developments - Genevant: Added reference to 'Favorable summary judgment decision' (newer filing, 2026-02-06)
- Removed:
- Pipeline table: Brepocitinib Dermatomyositis 'Phase 3 Completed*' designation removed (older filing, 2025-11-10)
- Pipeline table: Brepocitinib Cutaneous Sarcoidosis 'Phase 2' designation removed (older filing, 2025-11-10)
- Vant Ownership note: References to 'VantAI' and 'Psivant' by original names removed; now shown as 'Proxima (formerly VantAI)' and 'PsiThera (formerly Psivant)' (newer filing, 2026-02-06)
- Upcoming Catalysts table: Batoclimab footnote note about first study reading out before end of 2025 removed (older filing, 2025-11-10)
- Recent Developments - Priovant: Phase 3 VALOR study details and 30 mg dosage information removed (older filing, 2025-11-10)
- Recent Developments - Priovant: Language about proof-of-concept trial for cutaneous sarcoidosis removed (older filing, 2025-11-10)
- Reworded:
- Brepocitinib phase status changed from 'Phase 3 Completed' to 'NDA Filed' for dermatomyositis indication (newer filing, 2026-02-06)
- Brepocitinib cutaneous sarcoidosis phase escalated from 'Phase 2' to 'Phase 3*' (newer filing, 2026-02-06)
- Batoclimab catalyst wording changed from 'Topline data released from Phase 3 trials' to 'Topline data from both Phase 3 trials' (newer filing, 2026-02-06)
- IMVT-1402 difficult-to-treat rheumatoid arthritis catalyst changed from 'Initial results from open label period 1 of potentially registrational trial' to 'Topline data from potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis' with timing moved to 2H 2026 (newer filing, 2026-02-06)
- Brepocitinib non-infectious uveitis timing changed from 'Phase 3 trials in non-infectious uveitis' expected '1H 2027' to '2H 2026' (newer filing, 2026-02-06)
- Recent Developments: Priovant section changed from discussing VALOR study Phase 3 completion to discussing positive Phase 2 cutaneous sarcoidosis results and NDA submission (newer filing, 2026-02-06)
- Recent Developments: Immunovant section updated to reference financing proceeds and cash runway extension language (newer filing, 2026-02-06)
- Notes:
- Newer filing covers period ended December 31, 2025; older filing covers period ended September 30, 2025—date changes in tables reflect different reporting periods
- Text in newer filing appears truncated at end of Genevant bullet point ('Favorable summary judgment decision in U.S. Moderna case affirms Geneva'); full sentence not available for complete assessment
- Pipeline phase designations represent material clinical development status changes (Phase 2 to Phase 3, Phase 3 to NDA Filed) that reflect actual clinical progression
Risk Factors
- Reworded:
- Page number changed from 46 (older filing) to 49 (newer filing) in the table of contents section
- Notes:
- The two texts appear nearly identical through the point where both are truncated at the same location mid-sentence ('whic'). The only detectable difference is the page number citation, which likely reflects document length differences rather than content changes in this Risk Factors section itself.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 18 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 7 sells ($8M) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 18 sells ($60M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 44 sells ($277M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ROIV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for ROIV from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Short interest (FINRA)
ROIV had 36,181,548 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ROIV had 5.01% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.13 days to cover at the same settlement.
- Reported short interest (shares) 36,181,548
- Short interest (% of shares outstanding) 5.01%
- Prior settlement (shares) 33,522,300
- Reported change 7.93%
- Days to cover (reported) 4.13
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Immunovant (IMVT)
- Priovant (subsidiary)
- Pulmovant (subsidiary)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Regeneron (REGN)
- Amgen (AMGN)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ROIV vs…
Roivant Sciences is found in…
Frequently asked questions
What does Roivant Sciences (ROIV) do?
Roivant Sciences is a biopharmaceutical company that utilizes a decentralized 'Vant' subsidiary model to accelerate the development and commercialization of innovative medicines. The company maintains a diversified pipeline targeting autoimmune and inflammatory diseases, with lead candidates including a JAK1/TYK2 inhibitor and an anti-FcRn monoclonal antibody. Beyond clinical therapeutics, Roivant also incubates discovery-stage ventures and health technology startups.
What sector is Roivant Sciences (ROIV) in?
Roivant Sciences (ROIV) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Roivant Sciences's (ROIV) competitors?
Notable peers of Roivant Sciences (ROIV) include Immunovant, Priovant (subsidiary), Pulmovant (subsidiary), AbbVie and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ROIV?
Yes — we hold 4 matched STOCK Act disclosures for ROIV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Roivant Sciences (ROIV) overbought or oversold right now?
Roivant Sciences (ROIV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ROIV come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.